Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VolitionRx’s SEC filings are packed with pages of nucleosomics data, clinical-trial updates and financing details that can overwhelm even seasoned analysts. Missing a single Form 8-K about a new licensing deal or overlooking insider buying in a Form 4 could distort your view of this diagnostics innovator. Stock Titan’s AI turns those dense disclosures into clear takeaways, so you can focus on the science and the numbers that move VNRX’s valuation.
Our platform ingests every submission to EDGAR the instant it drops and produces plain-English highlights, red-flag alerts and side-by-side comparisons. Whether you’re searching for “VolitionRx quarterly earnings report 10-Q filing” or need “VolitionRx insider trading Form 4 transactions” before market open, we have you covered. Key documents are mapped to the insights they contain:
- 10-K / annual report — cash-burn trends, patent status, and pipeline milestones in one “VolitionRx annual report 10-K simplified” summary.
- 10-Q / quarterly earnings — segment spending, licensing revenue and trial enrollment metrics with concise “VolitionRx earnings report filing analysis”.
- 8-K — real-time alerts on material events; think “VolitionRx 8-K material events explained” minutes after filing.
- Form 4 — “VolitionRx Form 4 insider transactions real-time” so you can track executive stock moves the moment they file.
- DEF 14A proxy — drill into “VolitionRx proxy statement executive compensation” without digging through appendices.
Use Stock Titan’s AI-powered summaries, red-flag detectors and historical sidebars to understand R&D spend, dilution risk and partnership economics—“understanding VolitionRx SEC documents with AI” has never been easier. Schedule custom alerts, export tables for models and compare “VolitionRx executive stock transactions Form 4” against peer trends, all from one screen.
Armistice Capital, LLC and Steven Boyd filed a joint Schedule 13G/A reporting shared beneficial ownership of 9,804,352 shares of VolitionRx Ltd common stock, representing 9.99% of the class. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice exercises voting and investment power over those securities under an Investment Management Agreement. Mr. Boyd, as managing member of Armistice Capital, is reported to share voting and dispositive power. The filing indicates no sole voting or dispositive power and affirms the holdings were acquired in the ordinary course of business and not for the purpose of changing control.
VolitionRX Limited (VNRX) reports a quarter marked by multiple equity financings and ongoing operational risks. The company raised net proceeds of approximately $6.4M from an August 2024 equity offering, $2.3M in March 2025 shares and warrants, $1.9M in December 2024 warrants and shares, and $5.8M net from the Lind offering, plus roughly $161,075 from ATM sales through June 30, 2025. Several warrant and pre-funded warrant issuances create potential dilution, with 58,234,651 potential common share equivalents excluded from diluted EPS as anti-dilutive. The filing discloses a going concern auditor opinion and identified material weaknesses in internal control over financial reporting. Product lines cited include Nu.Q Vet, Nu.Q NETs, Nu.Q Discover and Capture-PCR™ alongside ongoing efforts to centralize accounting and strengthen controls.
Lagoda Investment Management, L.P. reports that its managed accounts held 11,705,000 shares of VolitionRX Ltd common stock as of June 30, 2025, representing 11.3% of the outstanding shares. The filing states the Reporting Person has sole voting and sole dispositive power over all 11,705,000 shares. The report cites 103,982,020 shares outstanding for VolitionRX used to calculate the percentage. The Schedule 13G/A indicates the stake is held in the ordinary course of business and was not acquired to influence control of the issuer.
On 08/05/2025, VolitionRx Ltd. (VNRX) director Guy Archibald Innes filed Form 4 reporting the purchase of 78,125 common shares at $0.64 per share, executed through the company’s registered direct offering. The transaction lifts his direct holding to 966,814 shares.
The filing also lists significant indirect ownership: 1,400,000 shares held by The Innes Family Bare Trust 2023 (where Innes is trustee), 356,000 shares held by The Dill Faulkes Educational Trust Ltd., and a combined 618,014 shares registered in the names of his son (309,006) and daughter (309,008). Innes shares voting/dispositive control over these blocks and disclaims beneficial ownership of the DFET position beyond any pecuniary interest.
No derivative securities were reported, and the form was signed on 08/06/2025.
VolitionRx Ltd. (VNRX) – Form 4 filing
On 08/05/2025, President, CEO & Director Cameron John Reynolds purchased 78,125 shares of common stock at $0.64 per share during the company’s registered direct offering (transaction code “P”). The acquisition raises his direct holdings to 2,609,847 shares. Reynolds also controls 1,007,718 shares through Concord International, Inc. and 34,076 shares held by his spouse, bringing his total beneficial ownership to roughly 3.65 million shares. No derivative securities were exercised or sold, and no dispositions were reported.
This insider buy represents an out-of-pocket investment of approximately $50,000, strengthening management’s alignment with shareholders. The shares were obtained via a primary issuance, indicating additional capital raised by the company.
Form 4 discloses that Salvatore T. Butera, CEO of Volition Veterinary and an officer of VolitionRx (VNRX), had 6,393 common shares automatically withheld on 01-Aug-2025 (code “F”) to cover taxes due on the vesting of 23,377 restricted stock units received in lieu of cash compensation. The withheld shares were cancelled by the company; neither the insider nor VolitionRx executed an open-market sale. After the transaction Mr. Butera owns 303,524 shares directly and 99,350 shares jointly with his spouse, keeping his overall economic stake largely intact. No derivative securities were transacted. Because the action was tax-related and not a discretionary sale or purchase, it carries limited insight into management’s view of valuation, but it does confirm the continued equity alignment of a key executive.
On 08/01/2025, VolitionRX Ltd. (VNRX) Chief Medical Officer Andrew Retter filed a Form 4 detailing an administrative, tax-related share withholding.
- 6,142 common shares were automatically withheld and cancelled (Transaction Code F) at an indicated price of $0.64 to satisfy tax obligations arising from the vesting of 13,069 restricted stock units that had been granted in lieu of cash compensation.
- Following the transaction, Retter’s direct beneficial ownership totals 131,632 common shares.
No open-market purchase or sale occurred, and the tiny reduction in outstanding shares is immaterial to VNRX’s capitalization. The filing therefore carries neutral informational value regarding insider sentiment or company fundamentals.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
